Cartesian Therapeutics, Inc.RNACNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank73
3Y CAGR+252.2%
5Y CAGR+23.9%
Studio
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
+252.2%/yr
vs -64.2%/yr prior
5Y CAGR
+23.9%/yr
Recent acceleration
Acceleration
+316.4pp
Accelerating
Percentile
P73
Within normal range
vs 5Y Ago
2.9x
Strong expansion
Streak
3 yr
Consecutive growthCompressed
PeriodValueYoY Change
202526.74+292.2%
20246.82+396.8%
20231.37+124.3%
20220.61-77.5%
20212.72-70.3%
20209.17+214.9%
20192.91-92.2%
201837.22-93.4%
2017566.76+4332.0%
201612.79-